60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
Go back to 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue| (NASDAQ: SXTP) | Delayed: 0.98 +0.06 (6.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.92 | 52 Week High | $ | |||
| Open | $0.92 | 52 Week Low | $ | |||
| Day High | $1.04 | P/E | N/A | |||
| Day Low | $0.91 | EPS | $ | |||
| Volume | 84,348 | |||||
| (NASDAQ: SXTPW) | Delayed: 0.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.03 | 52 Week High | $ | |||
| Open | $0.03 | 52 Week Low | $ | |||
| Day High | $0.03 | P/E | N/A | |||
| Day Low | $0.03 | EPS | $ | |||
| Volume | 132 | |||||
